Breast cancer bone metastases: denosumab or zoledronic acid?

被引：0
|
作者：
Gabri van der Pluijm
机构：
[1] Leiden University Medical Center,Department of Urology J3
来源：
Nature Reviews Endocrinology | 2011年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Bone metastases cause patient morbidity and mortality. A recent study compared denosumab with zoledronic acid for the treatment of bone metastases in advanced breast cancer. Denosumab seemed to be the front-runner, but is that the whole story?
引用
收藏
页码：134 / 135
页数：1
相关论文
共 50 条
  • [21] Denosumab and zoledronic acid (ZA) treatment in patients with genitourinary (GU) cancers and bone metastases
    Ganju, Vinod
    Costa, Luis
    Fizazi, Karim
    Saad, Fred
    Brown, Janet
    von Moos, Roger
    Oudard, Stephane
    Sternberg, Cora N.
    Miller, Kurt
    Wang, Huei
    Maniar, Tap
    Braun, Ada
    [J]. BJU INTERNATIONAL, 2013, 112 : 11 - 11
  • [22] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Rader, Michael
    Goessl, Carsten
    Cong, Ze
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (01): : 74 - 75
  • [23] Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid
    Cleeland, Charles S.
    Body, Jean-Jacques
    Stopeck, Alison
    von Moos, Roger
    Fallowfield, Lesley
    Mathias, Susan D.
    Patrick, Donald L.
    Clemons, Mark
    Tonkin, Katia
    Masuda, Norikazu
    Lipton, Allan
    de Boer, Richard
    Salvagni, Stefania
    Oliveira, Celia Tosello
    Qian, Yi
    Jiang, Qi
    Dansey, Roger
    Braun, Ada
    Chung, Karen
    [J]. CANCER, 2013, 119 (04) : 832 - 838
  • [24] HEALTH RESOURCE UTILIZATION OF SUBJECTS RECEIVING DENOSUMAB AND ZOLEDRONIC ACID IN A RANDOMIZED PHASE 3 TRIAL OF ADVANCED BREAST CANCER PATIENTS WITH BONE METASTASES
    Body, J. J.
    von Moos, R.
    Stopeck, A.
    Qian, Y.
    Braun, A.
    Chung, K.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A279 - A279
  • [25] Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).
    Smith, Matthew Raymond
    Brown, Janet Elizabeth
    Fizazi, Karim
    Klotz, Laurence
    Marx, Gavin M.
    Wang, Huei
    Warner, Douglas
    Lipton, Allan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [26] Comparing the Effects of Denosumab and Zoledronic Acid on Pain Interference with Daily Functioning in a Randomized Phase 3 Trial of Patients with Breast Cancer and Bone Metastases
    Cleeland, C. S.
    Patrick, D. L.
    Fallowfield, L.
    Clemons, M.
    Lipton, A.
    Masuda, N.
    Qian, Y.
    Braun, A.
    Chung, K.
    [J]. CANCER RESEARCH, 2010, 70
  • [27] Zoledronic acid in lung cancer with bone metastases: a review
    Isla, Dolores
    Afonso, Ruth
    Bosch-Barrera, Joaquim
    Martinez, Natividad
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (04) : 421 - 426
  • [28] Zoledronic acid for the treatment of bone Metastases in patients with breast cancer and other solid tumors
    Lacerna, L
    Hohneker, J
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (05) : 150 - 160
  • [29] Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
    Ito, Tokiko
    Ono, Mayu
    Oba, Takaaki
    Hanamura, Toru
    Kanai, Toshiharu
    Maeno, Kazuma
    Hiraguri, Manabu
    Shingu, Kiyoshi
    Kaneko, Gengo
    Ito, Ken-ichi
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [30] IMPAIRMENT OF RENAL FUNCTION IN THE BREAST CANCER PATIENTS WITH BONE METASTASES TREATED WITH ZOLEDRONIC ACID
    Ito, T.
    Shingu, K.
    Kaneko, G.
    Ito, K. -I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
12345